vs
Side-by-side financial comparison of Dynatrace, Inc. (DT) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $515.5M, roughly 1.4× Dynatrace, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 7.8%, a 11.3% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 18.2%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $27.2M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 16.3%).
Dynatrace, Inc. is an American multinational technology company that provides an AI-powered observability platform. Their software is used to monitor, analyze, and optimize application performance, software development, cyber security practices, IT infrastructure, and user experience.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
DT vs MEDP — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $515.5M | $708.5M |
| Net Profit | $40.1M | $135.1M |
| Gross Margin | 81.4% | — |
| Operating Margin | 14.1% | 21.6% |
| Net Margin | 7.8% | 19.1% |
| Revenue YoY | 18.2% | 32.0% |
| Net Profit YoY | -88.9% | 15.5% |
| EPS (diluted) | $0.13 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $515.5M | $708.5M | ||
| Q3 25 | $493.8M | $659.9M | ||
| Q2 25 | $477.3M | $603.3M | ||
| Q1 25 | $445.2M | $558.6M | ||
| Q4 24 | $436.2M | $536.6M | ||
| Q3 24 | $418.1M | $533.3M | ||
| Q2 24 | $399.2M | $528.1M | ||
| Q1 24 | $380.8M | $511.0M |
| Q4 25 | $40.1M | $135.1M | ||
| Q3 25 | $57.2M | $111.1M | ||
| Q2 25 | $48.0M | $90.3M | ||
| Q1 25 | $39.3M | $114.6M | ||
| Q4 24 | $361.8M | $117.0M | ||
| Q3 24 | $44.0M | $96.4M | ||
| Q2 24 | $38.6M | $88.4M | ||
| Q1 24 | $37.9M | $102.6M |
| Q4 25 | 81.4% | — | ||
| Q3 25 | 81.8% | — | ||
| Q2 25 | 82.1% | — | ||
| Q1 25 | 80.9% | — | ||
| Q4 24 | 81.1% | — | ||
| Q3 24 | 81.4% | — | ||
| Q2 24 | 81.3% | — | ||
| Q1 24 | 81.1% | — |
| Q4 25 | 14.1% | 21.6% | ||
| Q3 25 | 14.8% | 21.5% | ||
| Q2 25 | 13.1% | 20.9% | ||
| Q1 25 | 9.6% | 20.3% | ||
| Q4 24 | 10.9% | 23.4% | ||
| Q3 24 | 11.2% | 21.1% | ||
| Q2 24 | 10.5% | 19.9% | ||
| Q1 24 | 6.1% | 20.4% |
| Q4 25 | 7.8% | 19.1% | ||
| Q3 25 | 11.6% | 16.8% | ||
| Q2 25 | 10.0% | 15.0% | ||
| Q1 25 | 8.8% | 20.5% | ||
| Q4 24 | 82.9% | 21.8% | ||
| Q3 24 | 10.5% | 18.1% | ||
| Q2 24 | 9.7% | 16.7% | ||
| Q1 24 | 10.0% | 20.1% |
| Q4 25 | $0.13 | $4.65 | ||
| Q3 25 | $0.19 | $3.86 | ||
| Q2 25 | $0.16 | $3.10 | ||
| Q1 25 | $0.12 | $3.67 | ||
| Q4 24 | $1.19 | $3.67 | ||
| Q3 24 | $0.15 | $3.01 | ||
| Q2 24 | $0.13 | $2.75 | ||
| Q1 24 | $0.13 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.2B | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.7B | $459.1M |
| Total Assets | $4.1B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.2B | $497.0M | ||
| Q3 25 | $1.3B | $285.4M | ||
| Q2 25 | $1.3B | $46.3M | ||
| Q1 25 | $1.1B | $441.4M | ||
| Q4 24 | $1.0B | $669.4M | ||
| Q3 24 | $1.0B | $656.9M | ||
| Q2 24 | $1.0B | $510.9M | ||
| Q1 24 | $836.9M | $407.0M |
| Q4 25 | $2.7B | $459.1M | ||
| Q3 25 | $2.8B | $293.6M | ||
| Q2 25 | $2.7B | $172.4M | ||
| Q1 25 | $2.6B | $593.6M | ||
| Q4 24 | $2.6B | $825.5M | ||
| Q3 24 | $2.1B | $881.4M | ||
| Q2 24 | $2.1B | $763.6M | ||
| Q1 24 | $2.0B | $671.5M |
| Q4 25 | $4.1B | $2.0B | ||
| Q3 25 | $4.1B | $1.8B | ||
| Q2 25 | $4.1B | $1.6B | ||
| Q1 25 | $4.1B | $1.9B | ||
| Q4 24 | $3.7B | $2.1B | ||
| Q3 24 | $3.3B | $2.1B | ||
| Q2 24 | $3.3B | $1.9B | ||
| Q1 24 | $3.4B | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $33.8M | $192.7M |
| Free Cash FlowOCF − Capex | $27.2M | $188.1M |
| FCF MarginFCF / Revenue | 5.3% | 26.6% |
| Capex IntensityCapex / Revenue | 1.3% | 0.6% |
| Cash ConversionOCF / Net Profit | 0.84× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $465.5M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $33.8M | $192.7M | ||
| Q3 25 | $32.0M | $246.2M | ||
| Q2 25 | $269.7M | $148.5M | ||
| Q1 25 | $162.8M | $125.8M | ||
| Q4 24 | $42.2M | $190.7M | ||
| Q3 24 | $23.6M | $149.1M | ||
| Q2 24 | $230.7M | $116.4M | ||
| Q1 24 | $131.7M | $152.7M |
| Q4 25 | $27.2M | $188.1M | ||
| Q3 25 | $27.8M | $235.5M | ||
| Q2 25 | $262.2M | $142.4M | ||
| Q1 25 | $148.2M | $115.8M | ||
| Q4 24 | $37.6M | $183.0M | ||
| Q3 24 | $20.1M | $138.5M | ||
| Q2 24 | $227.4M | $103.5M | ||
| Q1 24 | $121.9M | $147.2M |
| Q4 25 | 5.3% | 26.6% | ||
| Q3 25 | 5.6% | 35.7% | ||
| Q2 25 | 54.9% | 23.6% | ||
| Q1 25 | 33.3% | 20.7% | ||
| Q4 24 | 8.6% | 34.1% | ||
| Q3 24 | 4.8% | 26.0% | ||
| Q2 24 | 57.0% | 19.6% | ||
| Q1 24 | 32.0% | 28.8% |
| Q4 25 | 1.3% | 0.6% | ||
| Q3 25 | 0.8% | 1.6% | ||
| Q2 25 | 1.6% | 1.0% | ||
| Q1 25 | 3.3% | 1.8% | ||
| Q4 24 | 1.1% | 1.4% | ||
| Q3 24 | 0.8% | 2.0% | ||
| Q2 24 | 0.8% | 2.4% | ||
| Q1 24 | 2.6% | 1.1% |
| Q4 25 | 0.84× | 1.43× | ||
| Q3 25 | 0.56× | 2.22× | ||
| Q2 25 | 5.62× | 1.65× | ||
| Q1 25 | 4.14× | 1.10× | ||
| Q4 24 | 0.12× | 1.63× | ||
| Q3 24 | 0.54× | 1.55× | ||
| Q2 24 | 5.97× | 1.32× | ||
| Q1 24 | 3.47× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DT
| Subscription And Circulation | $493.4M | 96% |
| Services | $22.1M | 4% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
